Metabolomic Evidence for a Field Effect in Histologically Normal and Metaplastic Tissues in Patients with Esophageal Adenocarcinoma

Patients with Barrett's esophagus (BO) are at increased risk of developing esophageal adenocarcinoma (EAC). Most Barrett's patients, however, do not develop EAC, and there is a need for markers that can identify those most at risk. This study aimed to see if a metabolic signature associate...

Full description

Saved in:

Bibliographic Details
Published in:	Neoplasia (New York, N.Y.) Vol. 19; no. 3; pp. 165 - 174
Main Authors:	Reed, Michelle A.C., Singhal, Rishi, Ludwig, Christian, Carrigan, John B., Ward, Douglas G., Taniere, Phillipe, Alderson, Derek, Günther, Ulrich L.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.03.2017 Elsevier
Subjects:	Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - pathology Antineoplastic Agents - therapeutic use Barrett Esophagus - metabolism Barrett Esophagus - pathology Case-Control Studies Esophageal Mucosa - metabolism Esophageal Mucosa - pathology Esophageal Neoplasms - drug therapy Esophageal Neoplasms - metabolism Esophageal Neoplasms - pathology Female Humans Magnetic Resonance Spectroscopy Male Metabolome Metabolomics - methods Metaplasia Oncology ML-PLS-DA NMR HGD EAC AUROC PLS-DA BO PCA partial least squares discriminant analysis nuclear magnetic resonance esophageal adenocarcinoma principle component analysis Barrett's esophagus multilevel partial least squares discriminant analysis area under the receiver operator curve high-grade dysplasia
ISSN:	1476-5586, 1522-8002, 1476-5586
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!